A kind of isradipine combination medicine, capsule, preparation method and application thereof

A technology of isradipine and capsules, applied in the field of pharmaceutical composition preparations, can solve the problems of slow taking effect, long duration and the like, and achieve the effect of good activity

Active Publication Date: 2016-06-29
CHONGQING CONQUER PHARML
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The drug works more slowly (2 to 4 weeks) and lasts longer

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of isradipine combination medicine, capsule, preparation method and application thereof
  • A kind of isradipine combination medicine, capsule, preparation method and application thereof
  • A kind of isradipine combination medicine, capsule, preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0012] The investigation of embodiment 1 isradipine combination drug capsule preparation method

[0013] Take the medicinal material according to the weight ratio of isradipine, ferulic acid, calcium sulfate, low-substituted hydroxypropyl cellulose, carboxymethyl cellulose and magnesium stearate in a ratio of 5:2:12:3:2:1, According to different processes, drug test groups were granulated, drug test group 1: purified water; drug test group 2: 50% ethanol; drug test group 3: 5% PVP; drug test group 4: 10% starch paste. All kinds of granules were taken, respectively packed by hard capsule filling machine, and the dissolution rate was checked by an intelligent dissolution apparatus according to the Pharmacopoeia method, and the corresponding dissolution rates of granules with different hardness of each variety were measured, and the results are shown in Table 1.

[0014] Table 1 Effect of different particle hardness on dissolution rate

[0015]

[0016] Take the original powd...

Embodiment 2

[0023] The preparation of embodiment 2 isradipine combination drug capsules

[0024] Take the medicinal materials according to the weight ratio of isradipine, ferulic acid, calcium sulfate, low-substituted hydroxypropyl cellulose, carboxymethyl cellulose and magnesium stearate in a ratio of 5:6:12:3:2:1, Isradipine, ferulic acid, calcium sulfate, low-substituted hydroxypropyl cellulose, carboxymethyl cellulose, and magnesium stearate are wetted with water and granulated, passed through a 100-mesh sieve, and no pressure is applied when the capsules are divided, Obtain drug experiment group I;

[0025] Take the medicinal material according to the weight ratio of isradipine, ferulic acid, calcium sulfate, low-substituted hydroxypropyl cellulose, carboxymethyl cellulose and magnesium stearate in a ratio of 5:2:12:3:2:1, According to the above-mentioned method, the drug experiment group II was obtained;

[0026] Take the medicinal materials according to the weight ratio of isradi...

Embodiment 3

[0027] Example 3 Experimental drug activity investigation on atherosclerosis

[0028] 64 male New Zealand white rabbits, weighing (1.67±0.21) kg. They were randomly divided into 8 groups with 8 animals in each group. The control group received normal pellet feed; the high-fat diet non-intervention group (hereinafter referred to as the non-intervention group) received high-cholesterol feed (1% cholesterol+5% lard pellet feed); the fluvastatin group (hereinafter referred to as the statin group) received high-cholesterol feed. Cholesterol feed + fluvastatin sodium capsule 20 mg, once a day; ferulic acid tablet group received high cholesterol feed + commercially available ferulic acid tablet 35 mg (weight of ferulic acid monomer), once a day; isradipine Tablet group was given high-cholesterol feed+commercially available isradipine tablet 50mg (isradipine monomer weight), once a day; drug experiment group I was given drug experiment group I 30mg (irradipine monomer weight) of high...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an isradipine composition medicine, aiming at bringing the medicine pair function of isradipine and ferulic acid in medicine combination into play. The medicine comprises active components, namely, isradipine and ferulic acid, in a weight ratio of (5-10): (2-6); the medicine pair function of isradipine and ferulic acid in medicine combination is brought into play; good activity is shown in treating atherosclerosis, and the activity is superior to that of independent medication of isradipine and ferulic acid.

Description

technical field [0001] The invention relates to a pharmaceutical composition preparation, more specifically to an isradipine combination medicine, capsule, preparation method and application thereof. technical background [0002] Isradipine (also known as: isradipine, iradipine), chemical name: isopropylmethyl(±)-4-(4-benzofurazanyl)-1,4-dihydro-2,6 -Dimethyl-3,6-pyridinedicarboxylate. It is a new type of dihydropyridine calcium channel blocker. Like other dihydropyridine drugs, it can effectively and selectively inhibit the contraction caused by depolarization by blocking the influx of transmembrane calcium ions. And play a role on cardiac muscle and vascular smooth muscle. This product has a strong vasodilator effect, but no heart inhibitory effect, and almost does not cause reflex tachycardia. Clinical and animal experiments have proved that the drug has obvious antihypertensive and anti-atherosclerotic effects. By maintaining or restoring the blood flow under the left...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/4439A61K9/48A61K47/38A61P9/12A61P9/10A61K31/192
Inventor 梅勇罗磊杨莉贺代琼唐建珍舒芬徐刚廖海燕
Owner CHONGQING CONQUER PHARML
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap